Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer

Sorafenib is a tyrosine kinase inhibitory drug with multiple molecular specificities that is approved for clinical use in second-line treatments of metastatic and advanced renal cell carcinomas (RCCs). However, only 10–40% of RCC patients respond on sorafenib-containing therapies, and personalizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gudkov, Alexander, Shirokorad, Valery, Kashintsev, Kirill, Sokov, Dmitriy, Nikitin, Daniil, Anisenko, Andrey, Borisov, Nicolas, Sekacheva, Marina, Gaifullin, Nurshat, Garazha, Andrew, Suntsova, Maria, Koroleva, Elena, Buzdin, Anton, Sorokin, Maksim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963850/
https://www.ncbi.nlm.nih.gov/pubmed/35359606
http://dx.doi.org/10.3389/fmolb.2022.753318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963850/
https://www.ncbi.nlm.nih.gov/pubmed/35359606
http://dx.doi.org/10.3389/fmolb.2022.753318

Ejemplares similares